NASDAQ: LRMR
Larimar Therapeutics Inc Stock Ownership - Who owns Larimar Therapeutics?

Insider buying vs selling

Have Larimar Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James E. FlynnDirector2025-07-313,387,529$3.20
$10.84MBuy
James E. FlynnDirector2025-07-313,387,539$3.20
$10.84MBuy
James E. FlynnDirector2025-07-312,599,932$3.20
$8.32MBuy

1 of 1

LRMR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LRMR insiders and whales buy or sell their stock.

LRMR Shareholders

What type of owners hold Larimar Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
James E. Flynn44.59%38,164,915$148.84MInsider
Deerfield Management Company LP24.81%21,231,974$82.80MInstitution
Peter Barrett12.01%10,276,057$40.08MInsider
Bruce Booth12.00%10,270,758$40.06MInsider
Ra Capital Management LP7.06%6,045,351$23.58MInstitution
Blue Owl Capital Holdings LP5.76%4,928,040$19.22MInstitution
Opaleye Management Inc4.80%4,110,000$16.03MInstitution
Millennium Management LLC4.27%3,655,189$14.26MInstitution
Blackrock Inc3.55%3,039,980$11.86MInstitution
Deerfield Partners LP3.25%2,777,777$10.83MInsider

1 of 3

LRMR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LRMR49.28%50.72%Net BuyingNet Buying
RCKT50.42%49.58%Net SellingNet Selling
FDMT76.15%23.85%Net Buying
ALT37.18%62.82%Net SellingNet Buying
CADL41.95%31.11%Net BuyingNet Buying

Larimar Therapeutics Stock Ownership FAQ

Who owns Larimar Therapeutics?

Larimar Therapeutics (NASDAQ: LRMR) is owned by 72.79% institutional shareholders, 74.91% Larimar Therapeutics insiders, and 0.00% retail investors. James E. Flynn is the largest individual Larimar Therapeutics shareholder, owning 38.16M shares representing 44.59% of the company. James E. Flynn's Larimar Therapeutics shares are currently valued at $139.30M.

If you're new to stock investing, here's how to buy Larimar Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.